DMN:FRA
Diamyd Medical AB
€ ०.०६३
०.००%
(०.००) 1D
नोभेम्बर १९, ०८:०१:५२ GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Mkt. cap
१४.२२ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Mkt. cap
१४.२२ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
Benzinga
·
२२ मिनेट पहिले
Stock Market: Will S&P 500 Open Up or Down Today?
FOREX.com
·
५७ मिनेट पहिले
S&P 500 Analysis: SPX Is Going Through One of Its Most Difficult Periods of 2026
Adam Feldman | Substack
·
१२ घण्टा पहिले
Inside the Federal Litigation of Five S&P 500 Giants
BigGo Finance
·
६ घण्टा पहिले
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB